Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells-Reference-Cited by-同舟云学术

Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells

Published:2011-09-23 Issue:4 Volume:26 Page:757-768
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Franke N E,Niewerth D,Assaraf Y G,van Meerloo J,Vojtekova K,van Zantwijk C H,Zweegman S,Chan E T,Kirk C J,Geerke D P,Schimmer A D,Kaspers G J L,Jansen G,Cloos J

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2011256.pdf

Reference48 articles.

1. Navon A, Ciechanover A . The 26 S proteasome: from basic mechanisms to drug targeting. J Biol Chem 2009; 284: 33713–33718.

2. Ortiz-Navarrete V, Seelig A, Gernold M, Frentzel S, Kloetzel PM, Hammerling GJ . Subunit of the ‘20S’ proteasome (multicatalytic proteinase) encoded by the major histocompatibility complex. Nature 1991; 353: 662–664.

3. Rivett AJ, Bose S, Brooks P, Broadfoot KI . Regulation of proteasome complexes by gamma-interferon and phosphorylation. Biochimie 2001; 83: 363–366.

4. Seifert U, Bialy LP, Ebstein F, Bech-Otschir D, Voigt A, Schroter F et al. Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 2010; 142: 613–624.

5. Crawford LJ, Walker B, Ovaa H, Chauhan D, Anderson KC, Morris TC et al. Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res 2006; 66: 6379–6386.

Cited by 151 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progression of monoclonal gammopathy of undetermined significance to multiple myeloma is associated with enhanced translational quality control and overall loss of surface antigens;Journal of Translational Medicine;2024-06-07

2. Proteasome Inhibitors in Multiple Myeloma;Hematology/Oncology Clinics of North America;2024-04

3. MYC the oncogene from hell: Novel opportunities for cancer therapy;European Journal of Medicinal Chemistry;2024-03

4. Interplay between proteasome inhibitors and NF-κB pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors;Cell Communication and Signaling;2024-02-08

5. Decoding the secrets: how conformational and structural regulators inhibit the human 20S proteasome;Frontiers in Chemistry;2024-01-08